Title of article
cholinergic anti-inflammatory pathway and covid-19
Author/Authors
mehranfard, danial nova southeastern university - college of pharmacy, florida, usa , speth, robert c. nova southeastern university - college of pharmacy, florida, usa , speth, robert c. georgetown university - school of medicine - department of pharmacology and physiology, washington, usa , speth, robert c. nova southeastern university - college of pharmacy, florida, usa , speth, robert c. georgetown university - school of medicine - department of pharmacology and physiology, washington, usa
From page
171
To page
174
Abstract
the cholinergic anti-inflammatory pathway (cap) first described by wang et al, 2003 has contemporary interest arising from the covid-19 pandemic. while tobacco smoking has been considered an aggravating factor in the severity of covid-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of covid-19 infections. this spotlight briefly describes the cap and its potential role as a therapeutic target for the treatment of covid-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
Keywords
cholinergic anti , inflammatory pathway , vagus nerve stimulation , alpha 7 nicotinic acetylcholine receptor , covid , 19
Journal title
Bioimpacts
Journal title
Bioimpacts
Record number
2704664
Link To Document